[Comparison of new cardiac agents using differential therapeutic criteria].
Positive inotropism, reduction in preload, and reduction in afterload induced by any cardiacum are not exactly quantified in humans, nor are the patients classified as to their respective requirements. Also, any of these drug activities change with the patient's instantaneous cardiac and hemodynamic functional state. One reason for incomplete knowledge is a shortage of methods which allow to assess the inotropic state of the myocardium. In 17 patients, age range 56-76 years (two females, 15 male), undergoing routine coronary surgery, informed consent was obtained for implantation of a needle transducer for measurement of wall force. At the end of coronary surgery, developed myocardial force and aorto-coronary bypass flow were measured electromagnetically. After control measurements, 0.03, 0.06 and 0.1 mg/kg enoximone were injected slowly (3 min per dose) into the aorto-coronary bypass. Eight to 18 h after surgery, and again 18-48 h after surgery, the following measurements were made, first as a control, and then after 1.5 mg/kg enoximone i.v.: aortic pressure (AoP), central venous pressure (CVP) and pulmonary artery pressure (PAP), cardiac output (CO), and heart rate (HR). Peripheral vascular resistance (TPR) was calculated. Developed force and its derivatives were recorded continuously. Immediately after recovery from cardioplegia a 0.19 mg/kg dose of enoximone injected over 9 min into the aorto-coronary bypass induced an increase in bypass flow of 64 +/- 30%. Mean arterial pressure (MAP) showed a fall 5 min after enoximon injection on both occasions. The values were 73 (+/- 3.7) to 67 (+/- 2.6) mmHg, and 83 (+/- 3.1) to 78 (+/- 2.8) mmHg, respectively. The increase obtained in cardiac output (CO) 6.0 (+/- 0.4) to 7.4 (+/- 0.7) l.min-1, and 6.2 (+/- 0.7) to 8.5 (+/- 1.3) l.min-1 was significant at 5 min and remained so at 30 min on both occasions.(ABSTRACT TRUNCATED AT 250 WORDS)
Redmann
K
K
Experimentelle Thorax-, Herz- und Gefässchirurgie, Universität Münster.
Lunkenheimer
P P
PP
Rettig
G
G
Isringhaus
H
H
Flameng
W
W
Demeyere
R
R
D000328:Adult; D000368:Aged; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D002316:Cardiotonic Agents; D001026:Coronary Artery Bypass; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017335:Enoximone; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology; D010726:Phosphodiesterase Inhibitors; D011183:Postoperative Complications / Q000188:drug therapy / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology
D002316:Cardiotonic Agents; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D017335:Enoximone
Vergleich neuer Kardiaka nach differentialtherapeutischen Kriterien.